Opinion|Videos|June 27, 2024
Phase 3 ECHO Trial: Study Design and Efficacy Data
Author(s)Brad S. Kahl, MD, Tycel Phillips, MD
The panelists evaluate the preliminary efficacy findings from the ECHO trial and address how the COVID-19 pandemic influenced overall survival outcomes in the study.
Advertisement
- What are your initial impressions of the efficacy data from ECHO?
- How did COVID impact OS for this trial data?
- Do you have clinical experience with BTKi’s in the frontline setting?
- If so, please share your experience.
Advertisement
Related to this article
Grade 3/4 neurotoxicity in patients prompted a partial clinical hold on the PALISADES-1 and PALISADES-2 trials of KITE-753 in large B-cell lymphoma.
In a phase 2 trial, orelabrutinib plus sintilimab yielded a 60.7% overall response rate in relapsed/refractory primary CNS lymphoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Closing the Gaps in Precision Oncology for Breast Cancer
2
KEYNOTE-B49 Points to a PD-L1-Defined Subset Benefiting From Immunotherapy in Breast Cancer
3
Navigating PD-L1–Low Gastroesophageal Cancer Treatment and Payer Challenges
4
Managing Patients With No Pathologic Response After Durvalumab Plus FLOT
5